Xin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin Xu has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Jianning Zhang
Department of Neurosurgery, Tianjin Medical University General Hospital
12 shared publications - Liqun Jiao
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
10 shared publications Bin Yang
8 shared publicationsFei Li
Department of Neurosurgery, Tianjin Bao Di Hospital, 8 Guangchuan Road, Tianjin, China
7 shared publicationsYingang Wu
Department of Neurosurgery, the First Affiliated Hospital, University of Science and Technology, Hefei, China
7 shared publicationsDongdong Sun
Department of Neurosurgery, Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin, China; Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, 154 Anshan Road, Tianjin, China
6 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71116
Thrombus Metabolism‐Based Molecular Subtyping for Prognostic Risk Stratification in Acute Ischemic Stroke: A Preliminary Study
Aims: To preliminarily characterize metabolic molecular subtypes of cerebral thromboemboli and evaluate their clinical significance in anterior circulation acute ischemic stroke due to large vessel occlusion (AIS‐LVO). Methods: Untargeted metabolomics was performed on thromboemboli retrieved from 36 patients with anterior circulation AIS‐LVO using ultra‐performance coupled liquid chromatography with quadrupole time‐of‐flight mass spectrometry (UPLC‐Q‐TOF‐MS). Unsupervised hierarchical clustering was employed to identify distinct metabolic molecular subtypes, and their associations with stroke etiology, radiographic severity, and functional outcomes were analyzed. Results: Two distinct thrombus metabolic molecular subtypes (C1 and C2) were identified based on 12 metabolites significantly associated with both short‐term (7‐day ∆NIHSS) and long‐term (90‐day mRS) functional outcomes. The C1 subtype, predominantly cardioembolic, exhibited enhanced lipid metabolism, whereas the C2 subtype, primarily atherothrombotic, demonstrated increased folate metabolism. Patients with C1 thromboemboli presented more severe admission ischemic lesions (as indicated by ASPECTS) and experienced poorer short‐term and long‐term outcomes. A six‐metabolite signature derived from LASSO regression was identified for exploratory discrimination of thrombus metabolic subtypes, etiological subtypes, and 90‐day outcomes. Conclusion: This preliminary exploratory study identifies two metabolically distinct thrombus molecular subtypes with clinical implications in anterior circulation AIS‐LVO, providing a novel basis for risk stratification and personalized secondary prevention and warrants further investigation.
- 30 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71116
Open AccessThrombus Metabolism‐Based Molecular Subtyping for Prognostic Risk Stratification in Acute Ischemic Stroke: A Preliminary Study
Aims: To preliminarily characterize metabolic molecular subtypes of cerebral thromboemboli and evaluate their clinical significance in anterior circulation acute ischemic stroke due to large vessel occlusion (AIS‐LVO). Methods: Untargeted metabolomics was performed on thromboemboli retrieved from 36 patients with anterior circulation AIS‐LVO using ultra‐performance coupled liquid chromatography with quadrupole time‐of‐flight mass spectrometry (UPLC‐Q‐TOF‐MS). Unsupervised hierarchical clustering was employed to identify distinct metabolic molecular subtypes, and their associations with stroke etiology, radiographic severity, and functional outcomes were analyzed. Results: Two distinct thrombus metabolic molecular subtypes (C1 and C2) were identified based on 12 metabolites significantly associated with both short‐term (7‐day ∆NIHSS) and long‐term (90‐day mRS) functional outcomes. The C1 subtype, predominantly cardioembolic, exhibited enhanced lipid metabolism, whereas the C2 subtype, primarily atherothrombotic, demonstrated increased folate metabolism. Patients with C1 thromboemboli presented more severe admission ischemic lesions (as indicated by ASPECTS) and experienced poorer short‐term and long‐term outcomes. A six‐metabolite signature derived from LASSO regression was identified for exploratory discrimination of thrombus metabolic subtypes, etiological subtypes, and 90‐day outcomes. Conclusion: This preliminary exploratory study identifies two metabolically distinct thrombus molecular subtypes with clinical implications in anterior circulation AIS‐LVO, providing a novel basis for risk stratification and personalized secondary prevention and warrants further investigation.
- Open Access
- 17 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Early risk stratification of acute postoperative deep vein thrombosis with inflammatory and hemostatic molecular markers in Chinese patients undergoing unicompartmental knee arthroplasty
Deep vein thrombosis (DVT) is a feared postoperative complication following knee arthroplasty. However, the incidence of acute DVT, associated early risk stratification models, and optimal thromboprophylaxis after unicompartmental knee arthroplasty (UKA) remain unclear. This study aimed to comprehensively evaluate the perioperative dynamics of systemic-inflammatory and hemostatic molecular markers in patients with knee osteoarthritis undergoing UKA and to analyze their association with the occurrence of acute DVT. The first multi-center prospective study enrolled consecutive patients undergoing unilateral UKA without routine postoperative pharmacological thromboprophylaxis from three institutions (two for derivation and one for external validation). Systemic-inflammatory and hemostatic molecular markers were measured at admission, 2-hour, 1-day, and 3-day post-UKA. Lower-extremity ultrasound was routinely conducted prior to and at 4-5 days following UKA to detect asymptomatic and symptomatic DVT. Temporal trends in these biomarkers and their relationship with acute DVT were analyzed. A nomogram was then developed to visualize individualized near-term risk stratification of acute postoperative DVT. Finally, a retrospective cohort of UKA-treated patients who received routine thromboprophylaxis was enrolled to evaluate the risk stratification performance of the identified indicators in an anticoagulated population. The derivation cohort included 87 patients (mean age 67.8 ± 6.5 years, 78.2% female), of whom 21 (24.1%) developed acute postoperative DVT (20 asymptomatic and 1 symptomatic). Multivariate Firth's penalized logistic regression identified that higher body mass index (BMI), and elevated postoperative day 3 levels of interleukin (IL)-6, thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) independently associated with an increased risk of acute DVT detected at 4-5 days post-UKA. A nomogram incorporating these four indicators demonstrated good discriminative ability, calibration, and exploratory net benefit. These findings were further validated in an independent external cohort (n = 42; mean age 67.2 ± 7.7 years; 69% female; DVT incidence, 23.8%) and in a separate cohort of 135 patients (mean age 66.4 ± 6.8 years; 77% female; DVT incidence, 20.7%) who received routine thromboprophylaxis. A preliminary nomogram incorporating BMI and postoperative day 3 levels of IL-6, TAT, and PIC serves as a promising auxiliary tool for near-term risk stratification of acute DVT detected at 4-5 days following UKA.
- 17 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Open AccessEarly risk stratification of acute postoperative deep vein thrombosis with inflammatory and hemostatic molecular markers in Chinese patients undergoing unicompartmental knee arthroplasty
Deep vein thrombosis (DVT) is a feared postoperative complication following knee arthroplasty. However, the incidence of acute DVT, associated early risk stratification models, and optimal thromboprophylaxis after unicompartmental knee arthroplasty (UKA) remain unclear. This study aimed to comprehensively evaluate the perioperative dynamics of systemic-inflammatory and hemostatic molecular markers in patients with knee osteoarthritis undergoing UKA and to analyze their association with the occurrence of acute DVT. The first multi-center prospective study enrolled consecutive patients undergoing unilateral UKA without routine postoperative pharmacological thromboprophylaxis from three institutions (two for derivation and one for external validation). Systemic-inflammatory and hemostatic molecular markers were measured at admission, 2-hour, 1-day, and 3-day post-UKA. Lower-extremity ultrasound was routinely conducted prior to and at 4-5 days following UKA to detect asymptomatic and symptomatic DVT. Temporal trends in these biomarkers and their relationship with acute DVT were analyzed. A nomogram was then developed to visualize individualized near-term risk stratification of acute postoperative DVT. Finally, a retrospective cohort of UKA-treated patients who received routine thromboprophylaxis was enrolled to evaluate the risk stratification performance of the identified indicators in an anticoagulated population. The derivation cohort included 87 patients (mean age 67.8 ± 6.5 years, 78.2% female), of whom 21 (24.1%) developed acute postoperative DVT (20 asymptomatic and 1 symptomatic). Multivariate Firth's penalized logistic regression identified that higher body mass index (BMI), and elevated postoperative day 3 levels of interleukin (IL)-6, thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) independently associated with an increased risk of acute DVT detected at 4-5 days post-UKA. A nomogram incorporating these four indicators demonstrated good discriminative ability, calibration, and exploratory net benefit. These findings were further validated in an independent external cohort (n = 42; mean age 67.2 ± 7.7 years; 69% female; DVT incidence, 23.8%) and in a separate cohort of 135 patients (mean age 66.4 ± 6.8 years; 77% female; DVT incidence, 20.7%) who received routine thromboprophylaxis. A preliminary nomogram incorporating BMI and postoperative day 3 levels of IL-6, TAT, and PIC serves as a promising auxiliary tool for near-term risk stratification of acute DVT detected at 4-5 days following UKA.
- Open Access
- 11 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (8)
Hyperadhesive von Willebrand Factor Contributes to Pathogenesis of Preeclampsia
BACKGROUND: Preeclampsia is the most common complication of pregnancy, significantly affecting maternal and fetal health, and is characterized by placental and systemic endotheliopathy. Patients with preeclampsia have elevated levels of VWF (von Willebrand Factor), which is associated with poor clinical outcomes. However, whether VWF serves merely as a marker for endotheliopathy or contributes to the pathogenesis of preeclampsia remains poorly understood. METHODS: We investigated the role of hyperadhesive VWF in the development of preeclampsia by studying patients, evaluating the phenotype of mouse models, and performing in vitro experiments. RESULTS: We show that patients develop VWF- and fibrin-rich thrombosis in the placenta and have significantly elevated levels of VWF adhesive activity and placenta-derived extracellular vesicles. In mouse models, pregnant wild-type mice infused with hyperadhesive VWF alone, or in combination with placenta-derived extracellular vesicles, developed a preeclampsia-like condition, which was reduced by the VWF-cleaving metalloprotease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif 13). Furthermore, ADAMTS13 -deficient mice with high baseline VWF (ADAMTS13 −/ −/casa ) developed a preeclampsia-like condition spontaneously, with VWF adhesive activity increasing 5.6-fold and placenta-derived extracellular vesicles increasing 2.9-fold during late pregnancy. VWF became hyperadhesive during pregnancy by undergoing conformational changes and promoted preeclampsia-associated endotheliopathy by enhancing the interaction of placenta-derived extracellular vesicles with endothelial cells. CONCLUSIONS: This study demonstrates that hyperadhesive VWF plays a causal role in preeclampsia and is a potential therapeutic target.
- 11 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (8)
Open AccessHyperadhesive von Willebrand Factor Contributes to Pathogenesis of Preeclampsia
BACKGROUND: Preeclampsia is the most common complication of pregnancy, significantly affecting maternal and fetal health, and is characterized by placental and systemic endotheliopathy. Patients with preeclampsia have elevated levels of VWF (von Willebrand Factor), which is associated with poor clinical outcomes. However, whether VWF serves merely as a marker for endotheliopathy or contributes to the pathogenesis of preeclampsia remains poorly understood. METHODS: We investigated the role of hyperadhesive VWF in the development of preeclampsia by studying patients, evaluating the phenotype of mouse models, and performing in vitro experiments. RESULTS: We show that patients develop VWF- and fibrin-rich thrombosis in the placenta and have significantly elevated levels of VWF adhesive activity and placenta-derived extracellular vesicles. In mouse models, pregnant wild-type mice infused with hyperadhesive VWF alone, or in combination with placenta-derived extracellular vesicles, developed a preeclampsia-like condition, which was reduced by the VWF-cleaving metalloprotease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif 13). Furthermore, ADAMTS13 -deficient mice with high baseline VWF (ADAMTS13 −/ −/casa ) developed a preeclampsia-like condition spontaneously, with VWF adhesive activity increasing 5.6-fold and placenta-derived extracellular vesicles increasing 2.9-fold during late pregnancy. VWF became hyperadhesive during pregnancy by undergoing conformational changes and promoted preeclampsia-associated endotheliopathy by enhancing the interaction of placenta-derived extracellular vesicles with endothelial cells. CONCLUSIONS: This study demonstrates that hyperadhesive VWF plays a causal role in preeclampsia and is a potential therapeutic target.
- Open Access
- 9 April 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Hematopoietic cell kinase regulates microglial/macrophage activation to drive neuroinflammation after traumatic brain injury
Brain-resident microglia and infiltrating monocyte-derived macrophages are among the main effectors in regulating innate immunity and mediating neuroinflammation after traumatic brain injury (TBI). Our previous work demonstrated that circulating extracellular vesicles from TBI patients (TEVs) aggravate microglial/macrophage activation and associated neuroinflammatory damage. However, the key molecular regulators governing TBI-induced and TEV-aggravated microglial/macrophage responses remain elusive. To identify key molecular regulators of microglial/macrophage activation during the acute phase after TBI, we first performed RNA-sequencing on mouse TBI brains at multiple acute time points, and on brains from TBI mice treated with TEVs. We then integrated and analyzed a public single-nucleus RNA-sequencing dataset from human TBI brains (GSE209552) to validate and extend our murine findings. After hub gene identification, we used complementary in vivo (TBI and TBI + TEV mice) and in vitro [oxygen-glucose deprivation/re-oxygenation (OGD/R)-stimulated and TEV-stimulated BV2 cells] models for mechanistic investigation. Multi-dimensional bioinformatics analyses identified six hub genes, including HCK, BLNK, C1QB, CTSC, P2RY6, and VAV1, consistently implicated in microglial/macrophage activation throughout the acute phase after TBI. Subsequent mechanistic investigations focused on hematopoietic cell kinase (HCK), a central node within this hub gene network. Pharmacological inhibition of HCK kinase activity with A-419259 was found to (1) alleviate TBI-induced and TEV-aggravated microglial/macrophage activation and recruitment, (2) promote a phenotypic shift from pro-inflammatory M1 toward anti-inflammatory/reparative M2 polarization, and (3) suppress the activation of microglial/macrophage nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. These effects collectively ameliorated secondary brain damage and improved neurological outcomes after TBI. Complementary in vitro studies confirmed that A-419,259 treatment alleviated OGD/R-stimulated or TEV-stimulated BV2 microglial activation and NLRP3 inflammasome activation, while facilitating the M1-to-M2 transition. Our findings identify HCK as a pivotal molecular regulator of microglia/macrophage-mediated neuroinflammation, thus providing a potential therapeutic target for ameliorating secondary brain injury after TBI. The online version contains supplementary material available at 10.1186/s12964-026-02871-7.
- 9 April 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessHematopoietic cell kinase regulates microglial/macrophage activation to drive neuroinflammation after traumatic brain injury
Brain-resident microglia and infiltrating monocyte-derived macrophages are among the main effectors in regulating innate immunity and mediating neuroinflammation after traumatic brain injury (TBI). Our previous work demonstrated that circulating extracellular vesicles from TBI patients (TEVs) aggravate microglial/macrophage activation and associated neuroinflammatory damage. However, the key molecular regulators governing TBI-induced and TEV-aggravated microglial/macrophage responses remain elusive. To identify key molecular regulators of microglial/macrophage activation during the acute phase after TBI, we first performed RNA-sequencing on mouse TBI brains at multiple acute time points, and on brains from TBI mice treated with TEVs. We then integrated and analyzed a public single-nucleus RNA-sequencing dataset from human TBI brains (GSE209552) to validate and extend our murine findings. After hub gene identification, we used complementary in vivo (TBI and TBI + TEV mice) and in vitro [oxygen-glucose deprivation/re-oxygenation (OGD/R)-stimulated and TEV-stimulated BV2 cells] models for mechanistic investigation. Multi-dimensional bioinformatics analyses identified six hub genes, including HCK, BLNK, C1QB, CTSC, P2RY6, and VAV1, consistently implicated in microglial/macrophage activation throughout the acute phase after TBI. Subsequent mechanistic investigations focused on hematopoietic cell kinase (HCK), a central node within this hub gene network. Pharmacological inhibition of HCK kinase activity with A-419259 was found to (1) alleviate TBI-induced and TEV-aggravated microglial/macrophage activation and recruitment, (2) promote a phenotypic shift from pro-inflammatory M1 toward anti-inflammatory/reparative M2 polarization, and (3) suppress the activation of microglial/macrophage nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. These effects collectively ameliorated secondary brain damage and improved neurological outcomes after TBI. Complementary in vitro studies confirmed that A-419,259 treatment alleviated OGD/R-stimulated or TEV-stimulated BV2 microglial activation and NLRP3 inflammasome activation, while facilitating the M1-to-M2 transition. Our findings identify HCK as a pivotal molecular regulator of microglia/macrophage-mediated neuroinflammation, thus providing a potential therapeutic target for ameliorating secondary brain injury after TBI. The online version contains supplementary material available at 10.1186/s12964-026-02871-7.
- Open Access
- 24 March 2026
- Published by Elsevier in Atherosclerosis Plus
- Vol. 65
Plasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk
- 24 March 2026
- Published by Elsevier in Atherosclerosis Plus
- Vol. 65
Open AccessPlasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk
- Open Access
- 2 October 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2477-2489
Associations of Folate and Homocysteine Levels with Futile Recanalization in Acute Ischemic Stroke After Successful Endovascular Thrombectomy
Introduction Our preliminary study identified two metabolically distinct thrombus subtypes, demonstrating enhanced lipid metabolic signatures but downregulated folate biosynthesis pathways associated with poor prognosis. This study aimed to assess the prognostic value of routine laboratory parameters involved in lipid and folate metabolism for predicting 90-day futile recanalization (FR) in patients with anterior circulation acute ischemic stroke caused by large vessel occlusion (AIS-LVO) who achieved successful recanalization by endovascular thrombectomy. Methods Consecutive patients with anterior circulation AIS-LVO who achieved successful recanalization (modified Thrombolysis in Cerebral Infarction score of 2b-3) were retrospectively screened from April 2019 to February 2024. Admission serum levels of traditional and non-traditional lipid parameters, folate, and homocysteine (Hcy) were measured. FR was defined as a 90-day modified Rankin Scale score of 3–6, despite successful recanalization. Multivariable logistic regression was performed to identify predictors for FR, which were incorporated into a predictive nomogram. Results Among 446 enrolled patients [median age 65 (IQR, 56–72.75) years; 32.1% female], 210 (47.1%) experienced 90-day FR. Multivariate logistic regression analysis revealed that lower admission serum folate and higher Hcy levels were independently associated with increased 90-day FR risk. In contrast, neither admission traditional or non-traditional lipid parameters were independent predictors. The addition of folate and Hcy, individually or combined, significantly improved the predictive performance of conventional clinical factor-based model, as reflected by significant increases in net reclassification improvement and integrated discrimination improvement. Finally, a predictive nomogram was developed incorporating age, admission National Institute of Health Stroke Scale, puncture-to-recanalization time, and admission serum glucose, folate, and Hcy levels. Conclusions Admission serum folate and Hcy levels are independent predictors of 90-day FR risk and may enhance risk stratification and guide personalized secondary prevention strategies in patients with successfully recanalized AIS-LVO.
- 2 October 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2477-2489
Open AccessAssociations of Folate and Homocysteine Levels with Futile Recanalization in Acute Ischemic Stroke After Successful Endovascular Thrombectomy
Introduction Our preliminary study identified two metabolically distinct thrombus subtypes, demonstrating enhanced lipid metabolic signatures but downregulated folate biosynthesis pathways associated with poor prognosis. This study aimed to assess the prognostic value of routine laboratory parameters involved in lipid and folate metabolism for predicting 90-day futile recanalization (FR) in patients with anterior circulation acute ischemic stroke caused by large vessel occlusion (AIS-LVO) who achieved successful recanalization by endovascular thrombectomy. Methods Consecutive patients with anterior circulation AIS-LVO who achieved successful recanalization (modified Thrombolysis in Cerebral Infarction score of 2b-3) were retrospectively screened from April 2019 to February 2024. Admission serum levels of traditional and non-traditional lipid parameters, folate, and homocysteine (Hcy) were measured. FR was defined as a 90-day modified Rankin Scale score of 3–6, despite successful recanalization. Multivariable logistic regression was performed to identify predictors for FR, which were incorporated into a predictive nomogram. Results Among 446 enrolled patients [median age 65 (IQR, 56–72.75) years; 32.1% female], 210 (47.1%) experienced 90-day FR. Multivariate logistic regression analysis revealed that lower admission serum folate and higher Hcy levels were independently associated with increased 90-day FR risk. In contrast, neither admission traditional or non-traditional lipid parameters were independent predictors. The addition of folate and Hcy, individually or combined, significantly improved the predictive performance of conventional clinical factor-based model, as reflected by significant increases in net reclassification improvement and integrated discrimination improvement. Finally, a predictive nomogram was developed incorporating age, admission National Institute of Health Stroke Scale, puncture-to-recanalization time, and admission serum glucose, folate, and Hcy levels. Conclusions Admission serum folate and Hcy levels are independent predictors of 90-day FR risk and may enhance risk stratification and guide personalized secondary prevention strategies in patients with successfully recanalized AIS-LVO.
- Open Access
Carotid Plaque‐Derived Small Extracellular Vesicles Mediate Atherosclerosis and Correlate With Plaque Vulnerability
Carotid plaque‐derived small extracellular vesicles (psEVs) offer insights into tissue‐ and disease‐specific pathobiology, but their roles in plaque vulnerability and their diagnostic potential remain unclear. Herein, we isolated psEVs from stable and vulnerable (intraplaque hemorrhage [IPH] or fibrous cap rupture [FCR]) plaques in patients with asymptomatic carotid artery stenosis (aCAS). Our findings demonstrated that psEVs alone were sufficient to induce inflammatory endothelial dysfunction in vitro and exacerbate atherogenesis in ApoE‐deficient mice. MicroRNA sequencing of psEVs (sequencing cohort, n = 18) identified 21 differentially expressed microRNAs (DEmiRNAs) distinguishing stable and vulnerable plaques, and 41 DEmiRNAs differentiating IPH from FCR subtypes. Subsequent validation using qRT‐PCR and the High‐throughput nano‐bio chip integrated system for liquid biopsy system revealed that plasma‐derived sEV miR‐497‐5p, miR‐152‐3p, and miR‐204‐5p effectively differentiated stable plaques from vulnerable plaques, while miR‐23a‐3p and miR‐143‐5p further distinguished IPH from FCR subtypes, in both the discovery cohort (n = 178) and an independent external cohort (n = 82). Mechanistic investigations identified miR‐497‐5p as a key mediator of vulnerable psEVs' proinflammatory and proatherogenic effects through directly targeting atheroprotective uncoupling protein 2 (UCP2). These findings highlight the roles of psEVs in atherogenesis and plaque vulnerability, providing valuable insights for risk stratification and therapeutic decision‐making in aCAS patients.
Open AccessCarotid Plaque‐Derived Small Extracellular Vesicles Mediate Atherosclerosis and Correlate With Plaque Vulnerability
Carotid plaque‐derived small extracellular vesicles (psEVs) offer insights into tissue‐ and disease‐specific pathobiology, but their roles in plaque vulnerability and their diagnostic potential remain unclear. Herein, we isolated psEVs from stable and vulnerable (intraplaque hemorrhage [IPH] or fibrous cap rupture [FCR]) plaques in patients with asymptomatic carotid artery stenosis (aCAS). Our findings demonstrated that psEVs alone were sufficient to induce inflammatory endothelial dysfunction in vitro and exacerbate atherogenesis in ApoE‐deficient mice. MicroRNA sequencing of psEVs (sequencing cohort, n = 18) identified 21 differentially expressed microRNAs (DEmiRNAs) distinguishing stable and vulnerable plaques, and 41 DEmiRNAs differentiating IPH from FCR subtypes. Subsequent validation using qRT‐PCR and the High‐throughput nano‐bio chip integrated system for liquid biopsy system revealed that plasma‐derived sEV miR‐497‐5p, miR‐152‐3p, and miR‐204‐5p effectively differentiated stable plaques from vulnerable plaques, while miR‐23a‐3p and miR‐143‐5p further distinguished IPH from FCR subtypes, in both the discovery cohort (n = 178) and an independent external cohort (n = 82). Mechanistic investigations identified miR‐497‐5p as a key mediator of vulnerable psEVs' proinflammatory and proatherogenic effects through directly targeting atheroprotective uncoupling protein 2 (UCP2). These findings highlight the roles of psEVs in atherogenesis and plaque vulnerability, providing valuable insights for risk stratification and therapeutic decision‐making in aCAS patients.
- Open Access
- 8 February 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-21
β2 integrin regulates neutrophil trans endothelial migration following traumatic brain injury
Neutrophils are the first responders among peripheral immune cells to infiltrate the central nervous system following a traumatic brain injury (TBI), triggering neuroinflammation that can exacerbate secondary tissue damage. The precise molecular controls that dictate the inflammatory behavior of neutrophils post-TBI, however, remain largely elusive. Our comprehensive analysis of the molecular landscape surrounding the trauma in TBI mice has revealed a significant alteration in the abundance of β2 integrin (ITGB2), predominantly expressed by neutrophils and closely associated with immune responses. Using the fluid percussion injury (FPI) mouse model, we investigated the therapeutic efficacy of Rovelizumab, an agent that blocks ITGB2. The treatment has demonstrated significant improvements in neurologic function in TBI mice, attenuating blood–brain barrier permeability, mitigating oxidative stress and inflammatory mediator release, and enhancing cerebral perfusion. Moreover, ITGB2 blockade has effectively limited the adherence, migration, and infiltration of neutrophils, and has impeded the formation of neutrophil extracellular traps (NETs) upon their activation. Finally, it was demonstrated that ITGB2 mediates these effects mainly through its interaction with intercellular adhesion molecule-1 (ICAM 1) of endotheliocyte. These findings collectively illuminate ITGB2 as a crucial molecular switch that governs the adverse effects of neutrophils post-TBI and could be targeted to improve clinical outcome in patients.
- 8 February 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-21
Open Accessβ2 integrin regulates neutrophil trans endothelial migration following traumatic brain injury
Neutrophils are the first responders among peripheral immune cells to infiltrate the central nervous system following a traumatic brain injury (TBI), triggering neuroinflammation that can exacerbate secondary tissue damage. The precise molecular controls that dictate the inflammatory behavior of neutrophils post-TBI, however, remain largely elusive. Our comprehensive analysis of the molecular landscape surrounding the trauma in TBI mice has revealed a significant alteration in the abundance of β2 integrin (ITGB2), predominantly expressed by neutrophils and closely associated with immune responses. Using the fluid percussion injury (FPI) mouse model, we investigated the therapeutic efficacy of Rovelizumab, an agent that blocks ITGB2. The treatment has demonstrated significant improvements in neurologic function in TBI mice, attenuating blood–brain barrier permeability, mitigating oxidative stress and inflammatory mediator release, and enhancing cerebral perfusion. Moreover, ITGB2 blockade has effectively limited the adherence, migration, and infiltration of neutrophils, and has impeded the formation of neutrophil extracellular traps (NETs) upon their activation. Finally, it was demonstrated that ITGB2 mediates these effects mainly through its interaction with intercellular adhesion molecule-1 (ICAM 1) of endotheliocyte. These findings collectively illuminate ITGB2 as a crucial molecular switch that governs the adverse effects of neutrophils post-TBI and could be targeted to improve clinical outcome in patients.
- Top Cited PapersOpen Access
Systemic-inflammatory indices and clinical outcomes in patients with anterior circulation acute ischemic stroke undergoing successful endovascular thrombectomy
- Open Access
- 15 March 2024
- Published by Eurasia Academic Publishing Group in Human Brain
- Vol. 3 (1)
Direct mechanical thrombectomy with or without thrombolysis for acute ischemic stroke
The efficacy of direct mechanical thrombectomy (MT) and thrombectomy combined with intravenous thrombolysis (MT+IVT) in patients with acute ischemic stroke is still unclear. To comprehensively analyze the two strategies, we conducted a meta-analysis of randomized controlled trials (RCTs). Six RCTs were recruited from Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials and published from 2020 to 2023, including 1164 in the MT group and 1170 in the MT + IVT group. There was no significant difference between the MT group and MT+IVT group in 90-day favorable outcome (OR 0.93, 95% CI 0.79-1.09, P=0.37, I2=0%,) and excellent outcome (OR 0.98, 95% CI 0.82-1.18, P=0.82, I2=0%). Similarly, there was no significant difference in 90-day mortality (OR 1.08, 95% CI 0.86-1.35, P=0.52, I2=0%) and symptomatic intracranial hemorrhage (OR 0.82, 95% CI 0.57-1.19, P=0.30, I2=0%). However, the successful recanalization rate of the MT group was significantly lower than that of the MT+IVT group (OR 0.73, 95% CI 0.57-0.94, P=0.01, I2=0%). There was no significant difference in functional outcome and safety endpoints between direct MT and MT+IVT, but the successful recanalization rate of MT+IVT was higher.
- 15 March 2024
- Published by Eurasia Academic Publishing Group in Human Brain
- Vol. 3 (1)
Open AccessDirect mechanical thrombectomy with or without thrombolysis for acute ischemic stroke
The efficacy of direct mechanical thrombectomy (MT) and thrombectomy combined with intravenous thrombolysis (MT+IVT) in patients with acute ischemic stroke is still unclear. To comprehensively analyze the two strategies, we conducted a meta-analysis of randomized controlled trials (RCTs). Six RCTs were recruited from Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials and published from 2020 to 2023, including 1164 in the MT group and 1170 in the MT + IVT group. There was no significant difference between the MT group and MT+IVT group in 90-day favorable outcome (OR 0.93, 95% CI 0.79-1.09, P=0.37, I2=0%,) and excellent outcome (OR 0.98, 95% CI 0.82-1.18, P=0.82, I2=0%). Similarly, there was no significant difference in 90-day mortality (OR 1.08, 95% CI 0.86-1.35, P=0.52, I2=0%) and symptomatic intracranial hemorrhage (OR 0.82, 95% CI 0.57-1.19, P=0.30, I2=0%). However, the successful recanalization rate of the MT group was significantly lower than that of the MT+IVT group (OR 0.73, 95% CI 0.57-0.94, P=0.01, I2=0%). There was no significant difference in functional outcome and safety endpoints between direct MT and MT+IVT, but the successful recanalization rate of MT+IVT was higher.